Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Aquestive Therapeutics reports strong Q1 performance and eyes global expansion

Aquestive Therapeutics' Q1 performance reflects strong revenue growth, debt reduction, and strategic advancements in product development.
While facing challenges in European pricing and Chinese market visibility, the company maintains a focus on operational efficiency and market expansion.
Opportunities in FDA interactions, market access, and upcoming regulatory meetings position Aquestive for future growth and product success.
Overall, Aquestive Therapeutics demonstrates resilience and strategic planning in navigating market challenges and driving growth.

Aquestive Therapeutics reports improved Q2 performance and eyes global expansion

Aquestive Therapeutics reported a strong Q2 2023 performance with revenue growth and reduced net loss. The company faces financial challenges but holds strengths in its financial position and growth outlook. Opportunities for expansion and partnerships present avenues for future growth.

Aquestive Therapeutics reports strong Q3 performance and optimistic growth outlook

Aquestive Therapeutics showcased robust financial performance, strategic debt refinancing, and promising product developments in Q3 2023. While facing challenges in competitive intelligence and trial efficiency, the company is optimistic about future growth opportunities and remains focused on expanding its capabilities.

Aquestive reports robust Q4 earnings, eyes billion-dollar sales opportunities

Aquestive Therapeutics showcases strong financial performance in Q4 2023, with revenue growth and improved EBITDA loss, setting a positive trajectory for future growth. Strategic focus on launching Anaphylm and Libervant, along with proactive commercial preparations, underlines the company's commitment to innovation and market expansion. Despite regulatory and competitive challenges, Aquestive's confidence in FDA processes and international market exploration present promising opportunities for long-term success.

Aquestive Therapeutics reports revenue growth and plans for future launches

Aquestive Therapeutics reported revenue growth in Q3 2024 driven by successful product launches and positive study results, despite increased expenses.
The company's focus on key programs and upcoming milestones signals a commitment to innovation and addressing market needs for sustained growth.
While facing challenges in managing expenses and profitability, Aquestive's strong financial position and strategic initiatives offer opportunities for future growth and market expansion.
Overall, Aquestive's performance in Q3 2024 reflects a balance between investment in future growth and financial stability, positioning the company for continued success.

Aquestive Therapeutics progresses towards Anaphylm launch amidst legal challenges

Aquestive Therapeutics is on track for Anaphylm launch, backed by strong data and strategic planning. Despite challenges with Libervant, the company remains committed to patient advocacy. Positive outlook for 2025 with key milestones and revenue guidance.

Aquestive Therapeutics reports Q1 financials, focuses on Anaphylm prelaunch success

Aquestive Therapeutics navigated Q1 2025 with a focus on Anaphylm's FDA review progress and commercial prelaunch activities. Despite financial challenges, the company is strategically reallocating resources and emphasizing marketing strategies for Anaphylm's success. Market volatility, regulatory hurdles, and international expansion efforts present both challenges and opportunities for Aquestive Therapeutics in the upcoming quarters.

Aquestive Therapeutics reports strong Q2 performance amidst market access focus

Aquestive Therapeutics' Q2 2025 performance reflects a company focused on innovation, market access, and international expansion for growth. Despite challenges in market access and regulatory interactions, the company's strengths in product development and financial stability position it well for the future. Navigating hurdles while seizing opportunities in FDA approval, market strategy execution, and product development will be critical for Aquestive Therapeutics' success.

Aquestive Therapeutics reports Q3 growth, eyes FDA approval for Anaphylm

Aquestive Therapeutics is navigating a mixed financial performance in Q3 2025 while focusing on the innovative Anaphylm program. Despite challenges like increased expenses and leadership changes, the company remains well-positioned for growth in 2026. Opportunities lie in the potential approval of Anaphylm, international expansion efforts, and strategic responses to market challenges.

Aquestive Therapeutics reports revenue growth and strategic readiness for Anaphylm

Aquestive Therapeutics demonstrated revenue growth and strategic progress in Q4 2025, poised for the potential U.S. launch of Anaphylm and FDA resubmission. With a focus on market readiness and commercial expansion, Aquestive is strengthening its market presence and innovation capabilities, despite regulatory and competitive challenges. The company's confidence in its pipeline, financial stability, and strategic initiatives positions Aquestive for future growth and market leadership in the pharmaceutical sector.